ABVC BioPharma Total Long Term Liabilities 2010-2025 | ABVC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ABVC BioPharma total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ABVC BioPharma total long term liabilities from 2010 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$222.8B
Amgen (AMGN)	$162B
Gilead Sciences (GILD)	$140.6B
Vertex Pharmaceuticals (VRTX)	$118.3B
Bristol Myers Squibb (BMY)	$96.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$76.5B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$42.3B
Argenex SE (ARGX)	$36.4B
BioNTech SE (BNTX)	$27.1B
Royalty Pharma (RPRX)	$20.8B
Insmed (INSM)	$19.3B
Biogen (BIIB)	$18.9B
Illumina (ILMN)	$17.4B
Genmab (GNMSF)	$15.2B
Genmab (GMAB)	$14.8B
Incyte (INCY)	$13.6B
Moderna (MRNA)	$13.1B
Exelixis (EXEL)	$12.1B
QIAGEN (QGEN)	$11.3B
BioMarin Pharmaceutical (BMRN)	$11.1B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10B
Bio-Techne Corp (TECH)	$9.2B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.6B